← Back to Search

Anti-inflammatory

Xiflam for Post-COVID Syndrome

Phase 2
Recruiting
Led By Peter Chang, MD
Research Sponsored by Inflammx Therapeutics Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Males with female partners of child-bearing potential must agree to use approved methods of contraception and agree to refrain from donating sperm for the duration of the study
Have recovered from the infection (tested negative for COVID-19)
Must not have
Intraocular surgery (including lens replacement surgery) within 3 months prior to randomization
History of laser therapy in the macular region
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

Summary

This trial aims to test if Xiflam is safe and effective compared to a placebo for patients with Long COVID. Xiflam or placebo will be given orally once a day for 12 weeks to

Who is the study for?
This trial is for individuals who have recovered from COVID-19 but are experiencing lingering effects known as Long COVID. The specifics of inclusion and exclusion criteria were not provided, so participants should inquire about detailed eligibility requirements.Check my eligibility
What is being tested?
The study aims to test the safety and effectiveness of a treatment called Xiflam compared to a placebo in patients with Long COVID. Participants will be randomly assigned to receive either Xiflam or placebo once daily for 12 weeks.See study design
What are the potential side effects?
Potential side effects of Xiflam are not specified in the provided information. As with any medication, there may be risks involved, which participants should discuss with the research team before joining.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I agree to use contraception and not donate sperm during the study.
Select...
I have recovered from COVID-19.
Select...
I've had new symptoms for 12+ weeks after a negative COVID-19 test.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have not had eye surgery in the last 3 months.
Select...
I have had laser therapy in the eye's macular area.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Primary Endpoint
Secondary outcome measures
Secondary Endpoint
Other outcome measures
Safety Endpoint

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: ExperimentalExperimental Treatment1 Intervention
IFX-LC001 Tonabersat tablets 40mg tablets or placebo Take two tablets once per day
Group II: PlaceboPlacebo Group1 Intervention
IFX-LC001Tonabersat tablets 40mg tablets or placebo Take two tablets once per day
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tonabersat
2006
Completed Phase 2
~710

Find a Location

Who is running the clinical trial?

Inflammx Therapeutics IncLead Sponsor
Peter Chang, MDPrincipal InvestigatorMassachusetts Eye Research and Surgery Institution (MERSI)
~10 spots leftby Mar 2025